NovaTears® Eye Drops Observational Study NT-002

NovaTears® Observational Study NT-002

This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.

Inclusion Criteria:

• According to NovaTears® instruction for use
• ≥ 18 years
• Patients with dry eye disease due to meibomian gland dysfunction applying eye lid hygiene for at least 14 days
• Ability and willingness to provide written Informed Consent
• Ability and willingness to participate in all examinations
• Willingness and ability to return for follow up visit

Exclusion Criteria:

• Patients with hypersensitivity to any of the components of NovaTears®
• Patients with contact lenses, pregnancies, or who are breast feeding
• Patients with dry eye disease not caused by meibomian gland dysfunction
• Patients taking lipid containing eye drops or requiring topical pharmacological treatment of dry eye disease